Loading...
Header Logo
Keywords
Last Name
Institution

Kelly M Standifer

TitleProfessor & Chair
InstitutionUniversity of Oklahoma Health Sciences Center
DepartmentPharmaceutical Sciences
Address1110 N Stonewall Ave
Oklahoma City OK 73117-1200
Phone405/271-6593
vCardDownload vCard

    Collapse Overview 

    Collapse Research 
    Collapse research activities and funding
    R29DA010738     (STANDIFER, KELLY M)Apr 1, 1996 - Feb 28, 2002
    NIH/NIDA
    OPIOID RECEPTOR SIGNAL TRANSDUCTION MECHANISMS
    Role: Principal Investigator

    R01DA017380     (STANDIFER, KELLY M)Apr 16, 2004 - Sep 30, 2009
    NIH/NIDA
    Cellular mechanisms of ORL1 regulation and cross talk
    Role: Principal Investigator

         (Standifer, KM)Jul 1, 2009 - Dec 31, 2010
    Department of the Army
    Blockade of nociceptin signaling reduces biochemical, structural and cognitive deficits after traumatic brain injury
    Role: PI

    W81XWH-11-2-0077     (Standifer, KM)Jan 15, 2011 - Feb 14, 2015
    Department of the Army
    Molecular mechanism of chronic pain and its modulation by posttraumatic stress disorder and Nociceptin/Orphanin FQ
    Role: PI

         (Standifer, KM)Jul 1, 2015 - Jun 30, 2016
    PHF
    Multi-modal protein and RNA visualization and quantification
    Role: PI

    HR17-041     (Standifer, KM)Aug 1, 2017 - Jul 31, 2020
    OCAST
    Post-traumatic stress disorder and co-morbid chronic pain: evidence that TNF imitates a sequelae involving Nociceptin/Orphanin FQ)
    Role: PI

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Awwad HO, Durand CD, Gonzalez LP, Tompkins P, Zhang Y, Lerner MR, Brackett DJ, Sherry DM, Awasthi V, Standifer KM. Post-blast treatment with Nociceptin/Orphanin FQ peptide (NOP) receptor antagonist reduces brain injury-induced hypoxia and signaling proteins in vestibulomotor-related brain regions. Behav Brain Res. 2016 Oct 25. PMID: 27793733.
      View in: PubMed
    2. Awwad HO, Gonzalez LP, Tompkins P, Lerner M, Brackett DJ, Awasthi V, Standifer KM. Blast Overpressure Waves Induce Transient Anxiety and Regional Changes in Cerebral Glucose Metabolism and Delayed Hyperarousal in Rats. Front Neurol. 2015; 6:132. PMID: 26136722; PMCID: PMC4470265.
    3. Zhang Y, Simpson-Durand CD, Standifer KM. Nociceptin/orphanin FQ peptide receptor antagonist JTC-801 reverses pain and anxiety symptoms in a rat model of post-traumatic stress disorder. Br J Pharmacol. 2015 Jan; 172(2):571-82. PMID: 24666365; PMCID: PMC4292969.
    4. Donica CL, Awwad HO, Thakker DR, Standifer KM. Cellular mechanisms of nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor regulation and heterologous regulation by N/OFQ. Mol Pharmacol. 2013 May; 83(5):907-18. PMID: 23395957; PMCID: PMC3629824.
    5. Zhang Y, Gandhi PR, Standifer KM. Increased nociceptive sensitivity and nociceptin/orphanin FQ levels in a rat model of PTSD. Mol Pain. 2012 Oct 20; 8:76. PMID: 23082795; PMCID: PMC3543245.
    6. Zhang Y, Donica CL, Standifer KM. Sex differences in the Nociceptin/Orphanin FQ system in rat spinal cord following chronic morphine treatment. Neuropharmacology. 2012 Sep; 63(3):427-33. PMID: 22575074; PMCID: PMC5009626.
    7. Donica CL, Ramirez VI, Awwad HO, Zaveri NT, Toll L, Standifer KM. Orphanin FQ/nociceptin activates nuclear factor kappa B. J Neuroimmune Pharmacol. 2011 Dec; 6(4):617-25. PMID: 21547539; PMCID: PMC3208742.
    8. Greenwood-Van Meerveld B, Standifer KM. Methylnaltrexone in the treatment of opioid-induced constipation. Clin Exp Gastroenterol. 2008; 1:49-58. PMID: 21677823; PMCID: PMC3108626.
    9. Bawa-Khalfe T, Altememi GF, Mandyam CD, Schwarz LA, Eikenburg DC, Standifer KM. The presence of beta2-adrenoceptors sensitizes alpha2A-adrenoceptors to desensitization after chronic epinephrine treatment. BMC Pharmacol. 2007 Dec 20; 7:16. PMID: 18096057; PMCID: PMC2234403.
    10. Salim S, Standifer KM, Eikenburg DC. Extracellular signal-regulated kinase 1/2-mediated transcriptional regulation of G-protein-coupled receptor kinase 3 expression in neuronal cells. J Pharmacol Exp Ther. 2007 Apr; 321(1):51-9. PMID: 17255468.
      View in: PubMed
    11. Sherry DM, Mitchell R, Standifer KM, du Plessis B. Distribution of plasma membrane-associated syntaxins 1 through 4 indicates distinct trafficking functions in the synaptic layers of the mouse retina. BMC Neurosci. 2006 Jul 13; 7:54. PMID: 16839421; PMCID: PMC1555595.
    12. Desai AN, Salim S, Standifer KM, Eikenburg DC. Involvement of G protein-coupled receptor kinase (GRK) 3 and GRK2 in down-regulation of the alpha2B-adrenoceptor. J Pharmacol Exp Ther. 2006 Jun; 317(3):1027-35. PMID: 16533872.
      View in: PubMed
    13. Ozsoy HZ, Thakker DR, Standifer KM. Orphanin FQ/nociceptin potentiates [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin-Induced mu-opioid receptor phosphorylation. Mol Pharmacol. 2005 Aug; 68(2):447-56. PMID: 15890842.
      View in: PubMed
    14. Desai AN, Standifer KM, Eikenburg DC. Cellular G protein-coupled receptor kinase levels regulate sensitivity of the {alpha}2b-adrenergic receptor to undergo agonist-induced down-regulation. J Pharmacol Exp Ther. 2005 Feb; 312(2):767-73. PMID: 15456839.
      View in: PubMed
    15. Desai AN, Standifer KM, Eikenburg DC. Simultaneous alpha2B- and beta2-adrenoceptor activation sensitizes the alpha2B-adrenoceptor for agonist-induced down-regulation. J Pharmacol Exp Ther. 2004 Nov; 311(2):794-802. PMID: 15192083.
      View in: PubMed
    16. Mandyam CD, Thakker DR, Standifer KM. Mu-opioid-induced desensitization of opioid receptor-like 1 and mu-opioid receptors: differential intracellular signaling determines receptor sensitivity. J Pharmacol Exp Ther. 2003 Sep; 306(3):965-72. PMID: 12750434.
      View in: PubMed
    17. Bawa T, Altememi GF, Eikenburg DC, Standifer KM. Desensitization of alpha 2A-adrenoceptor signalling by modest levels of adrenaline is facilitated by beta 2-adrenoceptor-dependent GRK3 up-regulation. Br J Pharmacol. 2003 Mar; 138(5):921-31. PMID: 12642394; PMCID: PMC1573738.
    18. Thakker DR, Ozsoy HZ, Standifer KM. Assessing opioid regulation of adenylyl cyclase activity in intact cells. Methods Mol Med. 2003; 84:29-37. PMID: 12703314.
      View in: PubMed
    19. Thakker DR, Standifer KM. Induction of G protein-coupled receptor kinases 2 and 3 contributes to the cross-talk between mu and ORL1 receptors following prolonged agonist exposure. Neuropharmacology. 2002 Nov; 43(6):979-90. PMID: 12423667.
      View in: PubMed
    20. Thakker DR, Standifer KM. Orphanin FQ/nociceptin blocks chronic morphine-induced tyrosine hydroxylase upregulation. Brain Res Mol Brain Res. 2002 Sep 30; 105(1-2):38-46. PMID: 12399106.
      View in: PubMed
    21. Mandyam CD, Thakker DR, Christensen JL, Standifer KM. Orphanin FQ/nociceptin-mediated desensitization of opioid receptor-like 1 receptor and mu opioid receptors involves protein kinase C: a molecular mechanism for heterologous cross-talk. J Pharmacol Exp Ther. 2002 Aug; 302(2):502-9. PMID: 12130708.
      View in: PubMed
    22. Yang H, Standifer KM, Sherry DM. Synaptic protein expression by regenerating adult photoreceptors. J Comp Neurol. 2002 Feb 11; 443(3):275-88. PMID: 11807837.
      View in: PubMed
    23. Sherry DM, Yang H, Standifer KM. Vesicle-associated membrane protein isoforms in the tiger salamander retina. J Comp Neurol. 2001 Mar 19; 431(4):424-36. PMID: 11223812.
      View in: PubMed
    24. Mathis JP, Mandyam CD, Altememi GF, Pasternak GW, Standifer KM. Orphanin FQ/nociceptin and naloxone benzoylhydrazone activate distinct receptors in BE(2)-C human neuroblastoma cells. Neurosci Lett. 2001 Feb 23; 299(3):173-6. PMID: 11165763.
      View in: PubMed
    25. Silva RM, Rossi GC, Mathis JP, Standifer KM, Pasternak GW, Bodnar RJ. Morphine and morphine-6beta-glucuronide-induced feeding are differentially reduced by G-protein alpha-subunit antisense probes in rats. Brain Res. 2000 Sep 08; 876(1-2):62-75. PMID: 10973594.
      View in: PubMed
    26. Mandyam CD, Altememi GF, Standifer KM. beta-Funaltrexamine inactivates ORL1 receptors in BE(2)-C human neuroblastoma cells. Eur J Pharmacol. 2000 Aug 18; 402(1-2):R1-37. PMID: 10940375.
      View in: PubMed
    27. Standifer KM. Reduction of neurotransmitter receptor and G-protein expression in vivo and in vitro by antisense oligodeoxynucleotide treatment. Methods Enzymol. 2000; 314:90-103. PMID: 10565007.
      View in: PubMed
    28. Wang H, Standifer KM, Sherry DM. GABA(A) receptor binding and localization in the tiger salamander retina. Vis Neurosci. 2000 Jan-Feb; 17(1):11-21. PMID: 10750823.
      View in: PubMed
    29. Brown GP, Yang K, Ouerfelli O, Standifer KM, Byrd D, Pasternak GW. 3H-morphine-6beta-glucuronide binding in brain membranes and an MOR-1-transfected cell line. J Pharmacol Exp Ther. 1997 Sep; 282(3):1291-7. PMID: 9316837.
      View in: PubMed
    30. Standifer KM, Pasternak GW. G proteins and opioid receptor-mediated signalling. Cell Signal. 1997 May-Jun; 9(3-4):237-48. PMID: 9218123.
      View in: PubMed
    31. Ryan-Moro J, Chien CC, Standifer KM, Pasternak GW. Sigma binding in a human neuroblastoma cell line. Neurochem Res. 1996 Nov; 21(11):1309-14. PMID: 8947921.
      View in: PubMed
    32. Ciszewska GR, Ginos JA, Charton M, Standifer KM, Brooks AI, Brown GP, Ryan-Moro JP, Berzetei-Gurske I, Toll L, Pasternak GW. Synthesis and characterization of substituted benzoylhydrazones of naloxone. Synapse. 1996 Oct; 24(2):193-201. PMID: 8890461.
      View in: PubMed
    33. Standifer KM, Rossi GC, Pasternak GW. Differential blockade of opioid analgesia by antisense oligodeoxynucleotides directed against various G protein alpha subunits. Mol Pharmacol. 1996 Aug; 50(2):293-8. PMID: 8700136.
      View in: PubMed
    34. Brooks AI, Standifer KM, Rossi GC, Mathis JP, Pasternak GW. Characterizing kappa3 opioid receptors with a selective monoclonal antibody. Synapse. 1996 Mar; 22(3):247-52. PMID: 9132993.
      View in: PubMed
    35. Standifer KM, Jenab S, Su W, Chien CC, Pan YX, Inturrisi CE, Pasternak GW. Antisense oligodeoxynucleotides to the cloned delta receptor DOR-1: uptake, stability, and regulation of gene expression. J Neurochem. 1995 Nov; 65(5):1981-7. PMID: 7595481.
      View in: PubMed
    36. Pasternak GW, Standifer KM. Mapping of opioid receptors using antisense oligodeoxynucleotides: correlating their molecular biology and pharmacology. Trends Pharmacol Sci. 1995 Oct; 16(10):344-50. PMID: 7491712.
      View in: PubMed
    37. Rossi GC, Standifer KM, Pasternak GW. Differential blockade of morphine and morphine-6 beta-glucuronide analgesia by antisense oligodeoxynucleotides directed against MOR-1 and G-protein alpha subunits in rats. Neurosci Lett. 1995 Sep 29; 198(2):99-102. PMID: 8592651.
      View in: PubMed
    38. Cheng J, Standifer KM, Tublin PR, Su W, Pasternak GW. Demonstration of kappa 3-opioid receptors in the SH-SY5Y human neuroblastoma cell line. J Neurochem. 1995 Jul; 65(1):170-5. PMID: 7790858.
      View in: PubMed
    39. Pan YX, Cheng J, Xu J, Rossi G, Jacobson E, Ryan-Moro J, Brooks AI, Dean GE, Standifer KM, Pasternak GW. Cloning and functional characterization through antisense mapping of a kappa 3-related opioid receptor. Mol Pharmacol. 1995 Jun; 47(6):1180-8. PMID: 7603458.
      View in: PubMed
    40. Visconti LM, Standifer KM, Schiller PW, Pasternak GW. TIPP[psi], a highly selective delta ligand. Neurosci Lett. 1994 Nov 07; 181(1-2):47-9. PMID: 7898768.
      View in: PubMed
    41. Standifer KM, Cheng J, Brooks AI, Honrado CP, Su W, Visconti LM, Biedler JL, Pasternak GW. Biochemical and pharmacological characterization of mu, delta and kappa 3 opioid receptors expressed in BE(2)-C neuroblastoma cells. J Pharmacol Exp Ther. 1994 Sep; 270(3):1246-55. PMID: 7932177.
      View in: PubMed
    42. Standifer KM, Chien CC, Wahlestedt C, Brown GP, Pasternak GW. Selective loss of delta opioid analgesia and binding by antisense oligodeoxynucleotides to a delta opioid receptor. Neuron. 1994 Apr; 12(4):805-10. PMID: 8161452.
      View in: PubMed
    43. Brooks AI, Standifer KM, Cheng J, Ciszewska G, Pasternak GW. Opioid binding in giant toad and goldfish brain. Receptor. 1994; 4(1):55-62. PMID: 8038707.
      View in: PubMed
    44. Standifer KM, Clark JA, Pasternak GW. Modulation of Mu1 opioid binding by magnesium: evidence for multiple receptor conformations. J Pharmacol Exp Ther. 1993 Jul; 266(1):106-13. PMID: 8392546.
      View in: PubMed
    45. Kepler KL, Standifer KM, Paul D, Kest B, Pasternak GW, Bodnar RJ. Gender effects and central opioid analgesia. Pain. 1991 Apr; 45(1):87-94. PMID: 1677751.
      View in: PubMed
    46. Standifer KM, Murthy LR, Kinouchi K, Steele L, Pasternak GW. Affinity labeling of mu and kappa receptors with naloxone benzoylhydrazone. Mol Pharmacol. 1991 Mar; 39(3):290-8. PMID: 1848652.
      View in: PubMed
    47. Arjune D, Standifer KM, Pasternak GW, Bodnar RJ. Reduction by central beta-funaltrexamine of food intake in rats under freely-feeding, deprivation and glucoprivic conditions. Brain Res. 1990 Dec 03; 535(1):101-9. PMID: 1963340.
      View in: PubMed
    48. Kinouchi K, Standifer KM, Pasternak GW. Modulation of mu 1, mu 2, and delta opioid binding by divalent cations. Biochem Pharmacol. 1990 Jul 15; 40(2):382-4. PMID: 2165406.
      View in: PubMed
    49. Paul D, Standifer KM, Inturrisi CE, Pasternak GW. Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite. J Pharmacol Exp Ther. 1989 Nov; 251(2):477-83. PMID: 2810109.
      View in: PubMed
    50. Standifer KM, Pitha J, Baker SP. Carbostyril-based beta-adrenergic agonists: evidence for long lasting or apparent irreversible receptor binding and activation of adenylate cyclase activity in vitro. Naunyn Schmiedebergs Arch Pharmacol. 1989 Jan-Feb; 339(1-2):129-37. PMID: 2566922.
      View in: PubMed
    51. Baker SP, Standifer KM, Kalberg CJ, Pitha J, Sumners C. Irreversible binding and recovery of the norepinephrine uptake system using an alkylating derivative of norepinephrine. J Neurochem. 1988 Apr; 50(4):1044-52. PMID: 2894406.
      View in: PubMed
    52. Milecki J, Baker SP, Standifer KM, Ishizu T, Chida Y, Kusiak JW, Pitha J. Carbostyril derivatives having potent beta-adrenergic agonist properties. J Med Chem. 1987 Sep; 30(9):1563-6. PMID: 2887658.
      View in: PubMed
    Standifer's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _